SEC Tracker
Get the app

Vistagen Therapeutics VTGN

Vistagen Therapeutics (VTGN) announced the resignation of its Chief Executive Officer, effective immediately. This leadership change comes at a critical juncture as the company navigates the development and regulatory approval process for its lead drug candidate, a potential breakthrough therapy for major depressive disorder. Investors should closely monitor the company's transition to new executive leadership and any potential impact on its strategic priorities and pipeline progress.

Form
8-K
Filed
Importance
Major

Open in the appGet the appView on EDGAR

Get an email when Vistagen Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Agenus AGEN public float $135M, Jun 30, 2025
  2. Voyager Therapeutics VYGR public float $144M, Jun 30, 2025
  3. Eledon Pharmaceuticals ELDN public float $145M, Jun 30, 2025
  4. Puma Biotechnology PBYI public float $145M, Jun 30, 2025
  5. Neurogene NGNE public float $146M, Jun 30, 2025